
    
      By enrolling patients with unresectable Renal Pelvic and Ureteral Neoplasms adapted to
      enrolled criteria, this study will document for the first time the safety and the short and
      long term efficacy of percutaneous IRE for unresectable Renal Pelvic and Ureteral Neoplasms.
    
  